Abstract
Glioblastoma (GBM) is one of the deadliest cancers. Treatment options are limited, and median patient survival is only several months. Translation of new therapies is hindered by a lack of GBM models that fully recapitulate disease heterogeneity. Here, we characterize two human GBM models (U87-luc2, U251-RedFLuc). In vitro, both cell lines express similar levels of luciferase and show comparable sensitivity to temozolomide and lapatinib exposure. In vivo, however, the two GBM models recapitulate different aspects of the disease. U87-luc2 cells quickly grow into large, well-demarcated tumors; U251-RedFLuc cells form small, highly invasive tumors. Using a new method to assess GBM invasiveness based on detecting tumor-specific anti-luciferase staining in brain slices, we found that U251-RedFLuc cells are more invasive than U87-luc2 cells. Lastly, we determined expression levels of ABC transporters in both models. Our findings indicate that U87-luc2 and U251-RedFLuc GBM models recapitulate different aspects of GBM heterogeneity that need to be considered in preclinical research.
| Original language | English |
|---|---|
| Article number | 844 |
| Journal | BMC Cancer |
| Volume | 22 |
| Issue number | 1 |
| DOIs | |
| State | Published - Dec 2022 |
Bibliographical note
Funding Information:This project was supported by funding from the US National Institutes of Health/National Institute of Neurological Disorders and Stroke (R01NS10754 to BB), startup funds from the University of Kentucky (to BB), the University of Kentucky College of Pharmacy (to JAS), the PhRMA Foundation Pre-Doctoral Fellowship (to JAS), the Dr. Joseph F. Pulliam Pilot Award by the University of Kentucky Markey Cancer Center (to JAS), and the Northern Kentucky/Greater Cincinnati UK Alumni Club Fellowship (to LTR). The content is solely the authors’ responsibility and does not necessarily represent the official views of the NINDS or the NIH.
Funding Information:
We thank the members of the Hartz and Bauer laboratories for proofreading the manuscript. This research was also supported by the Shared Resource Facilities of the University of Kentucky Markey Cancer Center (P30 CA177558), namely the Biospecimen Procurement and Translational Pathology Shared Resource Facility, and by the University of Kentucky Magnetic Resonance Imaging and Spectroscopy Center. Tissue samples were provided by the NCI Cooperative Human Tissue Network (CHTN). Other investigators may have received specimens from the same tissue specimens. Brain samples from Normal Control Individuals were provided by the University of Kentucky Tissue Bank (IRB #B15-2602-M). The UK Tissue Bank and the Aperio ScanScope XT are supported by the University of Kentucky Sanders-Brown Center on Aging ADC grant (P30AG028383).
Funding Information:
We thank the members of the Hartz and Bauer laboratories for proofreading the manuscript. This research was also supported by the Shared Resource Facilities of the University of Kentucky Markey Cancer Center (P30 CA177558), namely the Biospecimen Procurement and Translational Pathology Shared Resource Facility, and by the University of Kentucky Magnetic Resonance Imaging and Spectroscopy Center. Tissue samples were provided by the NCI Cooperative Human Tissue Network (CHTN). Other investigators may have received specimens from the same tissue specimens. Brain samples from Normal Control Individuals were provided by the University of Kentucky Tissue Bank (IRB #B15-2602-M). The UK Tissue Bank and the Aperio ScanScope XT are supported by the University of Kentucky Sanders-Brown Center on Aging ADC grant (P30AG028383).
Publisher Copyright:
© 2022, The Author(s).
Keywords
- ABC transporters
- Glioblastoma
- Invasiveness
- U251-RedFLuc
- U87-luc2
ASJC Scopus subject areas
- Oncology
- Genetics
- Cancer Research
